Extensil

Quick links to important sections

Extensil

Method of action: Urologicals

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Extensil

Quick Facts

Property Description
Active Ingredient Dapoxetine hydrochloride
Form Oral, film-coated tablet
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
Common Use Management of Premature Ejaculation (PE)
Origin Synthetic compound

Extensil: Definition and General Therapeutic Purpose

Extensil is a synthetic pharmaceutical preparation intended for the management of male sexual dysfunction, specifically designed to address premature ejaculation (PE) in adult men. The core purpose of this medication is to help patients achieve a greater degree of control over the timing of ejaculation, which is clinically recognized as a primary therapeutic goal for PE. Dapoxetine is an oral agent developed and approved specifically for the treatment of PE in adult men. This characterizes its position as a dedicated therapeutic option in the urological field, serving to extend the latency period before climax.

What Type of Medicine is Dapoxetine (Extensil)?

Extensil contains the active ingredient Dapoxetine, supplied as Dapoxetine hydrochloride, which is pharmacologically classified as a Selective Serotonin Reuptake Inhibitor (SSRI). Under the Anatomical Therapeutic Chemical (ATC) system, it is classified under the code G04BX14 (Other urologicals). A key differentiating factor of Dapoxetine is its unique short half-life, which enables it to be used on-demand rather than requiring chronic, daily administration, unlike long-acting SSRIs typically used for mood disorders. The pharmacokinetic profile involves rapid absorption and elimination. The drug is only available by prescription and is specifically positioned for use in adult men.

Composition and Pharmaceutical Form

The compound is a synthetic molecule, and the medication is typically manufactured as a single-entity product, focusing its therapeutic effect entirely on the action of Dapoxetine. Its standard pharmaceutical preparation is an oral, film-coated tablet. The composition consists primarily of the active drug, Dapoxetine hydrochloride, combined with various inactive excipients that form the solid matrix necessary for the tablet's structural integrity and its oral route of administration.

What side effects are possible with Extensil?

Possible Side Effects and Safety Information

The safety profile of Extensil (Dapoxetine) is documented in official regulatory materials, which classify adverse reactions by frequency and affected body system. Incidence rates are generally higher with the 60 mg dose compared to the 30 mg dose.

Frequency-Classified Adverse Reactions

Classification Adverse Reactions Listed
Very Common (ge 1/10) Nausea, Dizziness, Headache
Common (ge 1/100 to < 1/10) Insomnia, Anxiety, Agitation, Restlessness, Decreased libido, Somnolence, Diarrhea, Dry mouth, Erectile dysfunction, Fatigue

Adverse events are also grouped into System-Organ Classes, including Nervous System Disorders, Gastrointestinal Disorders, and Psychiatric Disorders.

Clinically Significant and Population Safety Notes

The official label highlights Syncope (loss of consciousness, often vasovagal in nature) as a clinically significant, documented adverse reaction. Syncope and its preceding symptoms are noted to occur more frequently after the first dose or within the first few hours of administration.

Extensil is contraindicated by regulatory bodies in patients with pre-existing significant pathological cardiac conditions (e.g., heart failure, certain conduction abnormalities) and in those with moderate to severe hepatic impairment. Use is generally restricted to men aged 18 to 64 years. Furthermore, a high-level safety note advises caution against situations where injury could result from sudden loss of consciousness, such as operating hazardous machinery.

Overdose and Emergency Response

The official regulatory profile for Extensil (Dapoxetine) overdose indicates that while clinical experience with high-dose ingestion is limited, the expected manifestations primarily involve Gastrointestinal (GIT) and Central Nervous System (CNS) disturbances. These common documented signs, extrapolated from high-dose clinical trials, include nausea, dizziness, diarrhea, headache, somnolence, and fatigue.

The most serious risk associated with high exposure is the potential for syncope (loss of consciousness), which may be accompanied by critical cardiovascular effects such as bradycardia (slowed heart rate) or sinus arrest. Due to the drug’s classification, the potential for Serotonin Syndrome is also recognized as a severe, life-threatening risk.

When to Seek Help: Regulatory instructions mandate that individuals experiencing severe or unexpected symptoms seek immediate medical attention. This urgent response is necessary because no specific antidote is known for Dapoxetine overdose; therefore, management is limited to symptomatic and supportive treatment, potentially including gastric lavage or activated charcoal. Official guidelines require continuous ECG monitoring and hospital observation to manage the potential for severe cardiac involvement. The risk of increased drug exposure and toxicity may be higher in patients with moderate to severe hepatic impairment.

Therapeutic Uses of Extensil

Extensil is used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. Therapeutic management involves supportive care for tension and sleep symptoms. This medication is applied across domains where increased discomfort or tension is present, and is relevant for easing symptoms that interfere with daily comfort.

Easing Discomfort and Supporting Stability

Extensil is used in areas where short-term symptom management is appropriate. It helps address symptom clusters that may become intense or disruptive, such as feelings of restlessness, general unease, and physical stiffness. This assistance is often used during phases when symptoms become more noticeable; it contributes to easing the overall symptom load. It is applicable in conditions marked by periods of increased physiological stress, providing supportive relief when symptoms interfere with routine activities.

Supporting Rest and Functional Comfort

Commonly used across conditions presenting with acute episodes of sleep difficulty, Extensil is relevant for managing symptoms that interfere with daily comfort. It is applied during phases where the patient experiences heightened discomfort or tension that disrupts the natural process of falling asleep, and supports general well-being during symptomatic phases.


Quick Fact: Support for Tension and Discomfort

Regulatory References

  1. Australian Therapeutic Goods Administration

Eligibility and Restrictions for Use

Official Eligibility for Extensil

Extensil is approved solely for use in adult men aged 18 to 64 years who have been officially diagnosed with Premature Ejaculation (PE) and meet all specific diagnostic criteria. Use is strictly limited to this demographic for which safety and efficacy data is established.

Populations For Whom Use is Contraindicated

The medicine must not be used in the following populations, as officially stated in the regulatory label:

  • Patients with Significant Pathological Cardiac Conditions, including heart failure (NYHA Class II-IV), sick sinus syndrome, or significant ischemic/valvular disease.
  • Patients with Moderate or Severe Hepatic Impairment (Child-Pugh Class B and C).
  • Patients with a history of Syncope (fainting) or severe psychiatric conditions such as mania or severe depression.
  • Patients taking Monoamine Oxidase Inhibitors (MAOIs), potent CYP3A4 inhibitors (like ketoconazole or ritonavir), or other medications with strong serotonergic effects.

Age and Condition Restrictions

Population Group Regulatory Status
Under 18 years (Pediatric) Use should not be used (Safety and efficacy not established).
65 years and over (Geriatric) Safety and efficacy have not been established (Limited data).
Severe Renal Impairment Use is not recommended.

The label also advises caution in men with mild to moderate renal impairment, and the medicine should be avoided in those prone to orthostatic reactions.

What should I know about interactions with other medicines?

Contraindicated Combinations and Timing Rules

The official regulatory profile for Extensil identifies several contraindicated substance classes. Co-administration is strictly prohibited with Monoamine Oxidase Inhibitors (MAOIs), Thioridazine, Potent CYP3A4 Inhibitors (such as ketoconazole), and other serotonergic agents (including SSRIs and St. John’s Wort). These prohibitions are due to the documented risks of Serotonin Syndrome, cardiac toxicity, or a significant, unsafe elevation in drug exposure. Mandatory timing rules govern switching therapies: a 7-day separation is required when starting Extensil after stopping a prohibited drug, and a 14-day separation is required when stopping Extensil and starting a prohibited drug. The medicine is also contraindicated in patients with moderate or severe hepatic impairment.


Metabolic and Pharmacodynamic Restrictions

Extensil is cleared primarily via the Cytochrome P450 enzyme system. Its regulatory profile requires caution and often a dose restriction when combined with Moderate CYP3A4 Inhibitors (like erythromycin) and Potent CYP2D6 Inhibitors, as these pharmacokinetic interactions can increase dapoxetine plasma concentration. Conversely, co-use with Potent CYP3A4 Inducers (like rifampicin) can reduce exposure. Pharmacodynamic cautions exist for Alcohol and other CNS-acting substances, which may enhance neurocognitive effects and the risk of syncope. Use with agents that cause vasodilation, such as PDE5 Inhibitors, requires caution due to an increased potential for orthostatic hypotension.

Mechanism of Action

Mechanism of Action: Inhibition of PDE5

Extensil's primary mechanism involves the selective inhibition of the Phosphodiesterase type 5 (PDE5) enzyme. This enzyme is predominantly localized in the smooth muscle cells of vascular tissue, notably within the corpus cavernosum and pulmonary arteries. By inhibiting PDE5, the drug prevents the enzymatic hydrolysis of the intracellular signaling molecule cyclic Guanosine Monophosphate (cGMP).

This interaction results in the preservation and accumulation of cGMP. Extensil acts as a signal potentiator within the Nitric Oxide (NO)-cGMP cascade, which is the primary pathway regulating vascular tone. The mechanism is dependent on the prior release of endogenous NO to initiate the cascade. The elevated and sustained concentration of cGMP subsequently triggers the relaxation of vascular smooth muscle and vasodilation. This physiological change is characterized by enhanced regional blood flow and establishes the foundation for the drug's activity.

Dosage and Administration Information

How to Use Extensil

Extensil (dapoxetine) is administered as an event-driven, oral therapy. The medication is available as film-coated tablets in two strengths: 30 mg and 60 mg. The administration protocol is focused on on-demand use and is not intended for continuous daily consumption.


Official Dosing and Administration Protocol

Instruction Category Description
Route of Administration The tablets are for oral use only.
Standard Dosing The initial dose is 30 mg. Treatment must not be initiated at the 60 mg dose.
Maximum Dose and Frequency The maximum recommended dose is 60 mg. A dose must not be taken more frequently than once every 24 hours.
Timing of Use To be taken 1 to 3 hours prior to anticipated sexual activity.
Ingestion Requirements May be taken with or without food. The tablets must be swallowed whole with at least one full glass of water.

Population-Specific Use Rules

Dosage recommendations include specific considerations for certain patient groups. Use is not recommended for patients with severe renal impairment (CrCL < 30 mL/min). The medicine is contraindicated in individuals with moderate or severe hepatic impairment. Furthermore, the efficacy and safety of dapoxetine have not been established in patients 65 years and over due to limited data.

Treatment continuation should be re-evaluated after the initial four weeks of treatment (or six doses) to assess the benefit-risk balance before proceeding with further therapy.

Recent Clinical Evidence

Extensil: Recent Clinical Evidence

This section summarizes the types of official research conducted on Extensil, focusing on the evidence structure used by regulatory bodies. The information is descriptive and does not offer medical advice.


Evidence for Use in Premature Ejaculation (PE)

The research base relies primarily on large, multi-center Randomized Controlled Trials (RCTs), where the medicine was compared against a placebo. Regulatory documents describe that these trials studied adult men who met specific clinical criteria for PE. Researchers monitored an objective measure, the Intravaginal Ejaculatory Latency Time (IELT), recorded by the partner using a stopwatch, and subjective patient-reported outcomes (PROs), such as perceived control and satisfaction. Studies report measurements of patterns observed in the trials concerning IELT and patient-reported changes on control and distress.


Evidence in Specific Groups and Research Gaps

The pivotal research focused heavily on adult men in stable, committed relationships. Trial designs show the core studies often excluded men with existing major psychiatric conditions, such as depression or anxiety. Specific research has, however, explored use in men also diagnosed with erectile dysfunction (ED), when Extensil was evaluated alongside another ED treatment.

Regarding follow-up, the primary effectiveness periods were typically structured for 12 weeks, with the longest duration documented in pivotal studies extending up to 24 weeks, or six months. Long-term effects are not fully established; data show patterns related to use over six months, but the consistency of those patterns over longer periods is not well characterized.

Finally, comparative evidence is lacking, meaning direct, head-to-head research against all other on-demand pharmacological treatments is scarce. The results apply only to the populations studied.

Key Studies & References

  1. Full evidence summary | Premature ejaculation: dapoxetine | NICE (National Institute for Health and Care Excellence)

Frequently Asked Questions (FAQ)

Common questions about Extensil (FAQ)


Q: Is Extensil known by any other names?

The medicine contains the active ingredient dapoxetine. In various countries where the drug is licensed and approved, it is marketed under specific brand names. One of the common brand names found across official regulatory documents is Priligy.


Q: Will I feel a difference immediately after starting Extensil?

Extensil is an on-demand medication intended to be taken 1 to 3 hours before anticipated activity. Pharmacological studies show the active substance reaches its maximum concentration in the bloodstream approximately one hour after administration. The intended action is tied to the required 1 to 3 hour timing window, as defined in regulatory guidelines.


Q: Is it normal to feel tired when you first start taking Extensil?

Yes, official safety documents classify fatigue (tiredness) and somnolence (sleepiness) as common side effects. Official patient information often notes that side effects associated with the medicine may improve as the body adjusts. However, if these symptoms are severe or persistent, it is important to communicate this to a healthcare provider.


Q: Do the side effects of Extensil usually go away after a while?

Official patient information often indicates that unwanted effects associated with the medicine may improve over time as the body adjusts. Treatment continuation should be re-evaluated after the initial period of use to assess the benefit-risk balance.


Q: Does Extensil interact with common pain relievers like ibuprofen?

Official regulatory documents do not list a specific interaction with common pain relievers such as ibuprofen. The focus of documented drug interactions is primarily on substances that strongly affect the drug's metabolism, such as certain potent CYP enzyme inhibitors.


Q: Are there any herbal supplements that interact with Extensil?

Yes, official warnings strictly prohibit co-administration with other serotonergic agents, which includes the herbal supplement St. John’s Wort. This is due to a documented risk of potentially harmful interactions that may occur.


Q: Is Extensil considered a long-term medication?

Extensil is specifically designed and intended for event-driven, on-demand use, and regulatory guidance confirms it is not intended for chronic, continuous daily administration. Clinical trials documented effectiveness and safety for use up to six months.


Q: Has Extensil been approved in other countries besides the US?

Yes, the medicine is licensed and approved for use in multiple countries globally. Regulatory documents from agencies like the European Medicines Agency (EMA) and the Australian Therapeutic Goods Administration (TGA) confirm its approval in those respective regions.


Q: How does the structure of Extensil allow it to work in the body?

The active substance, dapoxetine, is chemically classified as a Selective Serotonin Reuptake Inhibitor (SSRI). This classification describes its ability to influence signaling molecules in the body, which is the foundation of its therapeutic action, according to official documents.


Q: Does Extensil stay in my system for a long time after I stop taking it?

Extensil is described as a short-acting agent. Pharmacokinetic studies show that the drug is cleared from the plasma relatively quickly, with the terminal half-life of the active substance reported to be approximately 19 hours. This rapid clearance allows for its on-demand use profile.


Q: Why is Extensil sometimes prescribed with another medication?

Clinical trials have evaluated the use of the medicine alongside an erectile dysfunction (ED) treatment in men who have both conditions. This approach was studied to address both conditions concurrently in an official research setting.


Q: What are the signs of a less common but serious side effect of Extensil?

The official label specifically highlights syncope (fainting or loss of consciousness) as a clinically significant adverse reaction. Official label information indicates that syncope may be preceded by symptoms such as feeling dizzy, light-headed, nauseous (sick), sweaty, or confused.


Q: Can I take Extensil if I have a history of heart issues?

The medicine is strictly contraindicated (is not allowed to be used) for individuals with pre-existing significant pathological cardiac conditions, as defined in the regulatory label. These conditions include heart failure (NYHA Class II-IV), sick sinus syndrome, or significant ischemic or valvular disease.


Q: Is Extensil gluten-free or lactose-free?

Information on the inactive ingredients (excipients) in the regulatory files indicates that the film-coated tablets may contain substances derived from sugars or sugar alcohols. This may include lactose or mannitol, depending on the formulation approved for your region.


Q: Do any official warnings exist about Extensil and mental health?

Yes, the medicine is strictly contraindicated for individuals with a history of severe psychiatric conditions, such as mania or severe depression. Official warnings also exist regarding its use in combination with other agents that affect serotonin levels.


Q: What is the difference between Extensil capsules and tablets (if applicable)?

Official product information, such as the Summary of Product Characteristics (SmPC), describes the only approved form of the medicine as a film-coated tablet, available in 30 mg and 60 mg strengths. No alternative capsule formulation is officially described or approved.


Q: What kind of specialist typically prescribes Extensil?

Guidance on the management of premature ejaculation indicates that prescribing of the medicine is typically initiated by primary care providers, such as General Practitioners (GPs), or specialized healthcare professionals like urology nurses and consultants.


Q: Does Extensil have a Patient Information Leaflet (PIL)?

Yes, regulatory requirements in many regions mandate that a Patient Information Leaflet (PIL) or package leaflet containing full official information for the user must be supplied with the medicine.


Q: What are the overall expectations for treatment with Extensil?

The therapeutic purpose described in official documentation is to help patients achieve a greater degree of control over the timing of ejaculation. The goal is also to reduce the frustration and worry associated with rapid ejaculation, which is the primary therapeutic target.


Q: How is Extensil different from other similar treatments for the same condition?

Extensil is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). A key factor noted in regulatory documents is its short half-life, which distinguishes it from many other SSRIs and allows it to be used on-demand rather than requiring continuous, daily administration.


Q: Can Extensil affect my ability to drive or operate machinery?

Official guidance advises caution if you feel dizzy, light-headed, or experience other adverse reactions, as the medicine may cause dizziness, sleepiness, or fainting (syncope). If these effects occur, official information advises against driving or using tools or machines.


Q: Is Extensil safe for women who are planning to become pregnant?

The medicine is strictly for use in adult men who meet the diagnostic criteria for premature ejaculation. Official documentation explicitly states that the medicine is not indicated and should not be taken by women.


Q: Can I take Extensil if I am already taking medication for high blood pressure?

Regulatory warnings advise caution when the medicine is used concurrently with agents that cause vasodilation (widening of blood vessels). This is due to a heightened potential for orthostatic hypotension (a drop in blood pressure when changing posture).


Q: Can I travel internationally while taking Extensil and what should I know?

The official storage requirements advise keeping the tablets in their original blister packaging and storing them below 25 C or 30 C (depending on the label). Following these general instructions helps to maintain the drug's stability during travel.


Q: Are there any common food or drink restrictions while taking Extensil?

The tablets may be taken with or without food. Official patient information warns that consuming alcohol may enhance certain neurocognitive effects, and therefore, co-use is cautioned. Furthermore, the consumption of grapefruit juice may increase the drug's concentration in the bloodstream, potentially raising the risk of side effects.

How should Extensil be stored and disposed of?

How to Store and Dispose of Extensil?

The storage and disposal of Extensil (dapoxetine) must follow the specific instructions on the product label to ensure its stability and safety. The medicine does not require any special storage conditions but should generally be kept in a cool, dry place and away from excessive heat or moisture.

Storage Requirements

Requirement Instruction
Temperature Store below 25 C or 30 C, depending on the labeled range.
Container Keep in the original blister pack until the time of use; do not use past the expiry date (EXP).
Child Safety Mandatory instruction: Keep this medicine out of the sight and reach of children.

Disposal

Do not throw away unused or expired Extensil via wastewater or household waste. The proper method is to ask your pharmacist about local drug take-back programs or for guidance on safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Extensil found in:

A-Z Index: